ArticleCancer cell international2026
Celastrol induces apoptosis of myelodysplastic syndrome cells through a ROS-dependent pro-apoptotic endoplasmic-reticulum stress pathway.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMyelodysplastic syndromes (MDS) represent clonal hematopoietic stem cell disorders with inherent propensity for leukemic transformation. Emerging evidence implicates dysregulated Endoplasmic-Reticulum stress (ER-stress) in sustaining malignant clones through adaptive suppression of pro-apoptotic PERK/CHOP signaling. Celastrol serves as a natural compound with documented ER-stress modulating activity in solid tumors. However, the beneficial effect and molecular mechanisms of celastrol on MDS are unknown.
objectiveThis investigation aims to determine whether celastrol inhibits MDS tumor cell proliferation, and molecular mechanisms of celastrol on MDS involved in the terminal pro-apoptotic ER-stress branches PERK/CHOP axis.
resultsCelastrol demonstrated cytotoxic effects against MDS cell lines (IC50 1.09 µM-2.02 µM) and primary patient-derived bone marrow mononuclear cells (n = 3, mean apoptosis rate: 42.6%). Flow cytometry results showed that celastrol can induced MDS-L and SKM-1 cell apoptosis. And celastrol treatment can elevate apoptotic protein expression, including cleaved PAPR1, rH2AX and cleaved caspase 3. Celastrol can induce ROS production, and the NAC pretreatment can eliminate the apoptosis-induced effect of celastrol. Our Bulk RNA-seq result of SKM-1 cell and the bone marrow sequencing results of patients with high-risk MDS (GSE19429) suggested that celastrol can activate the terminal pro-apoptotic ER-stress branches PERK/CHOP axis. In consistent, electron microscope screen found celastrol can induce ER Swelling and thickening in a ROS-dependent manner. In vitro experiments, celastrol can increase the eIF2α-ATF4-CHOP protein expression in a ROS-dependent manner. Molecular docking (ΔG -10.9 kcal/mol) and CETSA suggested celastrol might bind to BIP protein. In vivo, celastrol monotherapy can reduce tumor burden in xenograft models. Moreover, in MDS-L cell, celastrol can synergistically enhance the effect of venetoclax, as a BCL2 inhibitor inducing tumor cell apoptosis.
conclusionThese results indicate that celastrol induces apoptosis in MDS cells and can activate the pro-apoptotic terminal ER-stress response in a ROS-dependent manner. Together, our findings suggest that ER stress activation plays a role in celastrol‑induced apoptosis in MDS cells, supporting further investigation of celastrol as a candidate for MDS therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.